Prof Ignace Vergote speaks to ecancer at ESMO 2023 about the innovaTV 301/ENGOT-cx12/GOG-3057 study.
This was a global, randomised, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in second line or third line recurrent or metastatic cervical cancer.
In the study results, tisotumab vedotin showed a statistically significant and clinically meaningful improvement in overall survival, progression free survival, and overall response rate versus chemotherapy, with a manageable and tolerable safety profile in patients with second line or third line recurrent or metastatic cervical cancer.